Thread: (IPCI) 6 Drugs awaiting FDA Approval (Mcap 51 M) = TOP PICK 2012

IPCI IS THE BEST AND THE MOST UNDERVALUED UNKNOWN GEM IN THE BIOTECH SECTOR BUT PLEASE DO YOUR OWN RESEARCH ! GLTA

This Unknown ULTRA LOW FLOAT Stock awaiting 6 FDA approvals.IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including a potential Blockbuster .

Market Cap 51 Mil / Cash 7.5 M / Burn-rate 4.5 M per Year = Enough Cash until Profitability which will happen THIS YEAR .

4x FDA APPROVALS IN 2012 = $10++ EASILY FOLKS !!!


Intellipharmaceutics (IPCI)

Market Cap:$ 51 M
Cash: $ 7.5 M
Price: $3.30

Shares Out: 15.9 Mil..(10 Mil Shares held by Insiders/Institutions)

SUPER LOW FLOAT: 3 M


MONSTER Pipeline
Intellipharmaceutics - Pipeline


New Article (IPCI worth $15++ per share )
Intellipharmaceutics: A Deep Value Opportunity In Generics And Specialty Pharmaceuticals - Seeking Alpha


CEO says multiple deals, FDA approvals and more filings are in the works
http://www.******************/201104...the-works.html


Intellipharmaceutics now has six ANDAs being reviewed by the FDA for approval, with reported sales by others for branded and generic versions of these products being approximately $6.6 billion for the 12 months ended September 2011. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.

..........................

Roth starts Intellipharmaceutics at buy | BioTuesday

Roth starts Intellipharmaceutics at buy
January 25, 2012

Roth Capital Partners has initiated coverage of Intellipharmaceutics (NASDAQ:IPCI; TSX:I) with a “buy” rating and 12-month price target of $5.25, saying the emerging generics company could launch four new products in the coming 12-to-18 months.

“We believe that this momentum could unlock value for this under covered stock,” writes analyst Scott Henry. The stock closed at $2.97 on Wednesday.

Intellipharmaceutics’ four upcoming product launches include generics of Focalin XR, Effexor XR, Protonix, and Glucophage XR. The lead product, Focalin XR for attention deficit hyperactivity disorder, is partnered with generic leader Par Pharmaceuticals.

“This product pipeline produces branded revenue near $5 billion and we believe that these generic offerings could produce near $100 million in end-user revenue potential for Intellipharmaceutics,” Mr. Henry points out.

He figures product launches could boost revenue from about $1 million in 2011 to nearly $20 million in 2013, with the company crossing over into profitability in the fourth quarter of 2012. For 2013, he predicts earnings per share of 30 cents.

Intellipharmaceutics also has an “entrant in the high-growth area of abuse-resistant opioids, which could be a multi-billion dollar market,” Mr. Henry said. “Although early, this gives investors another way to win, in our opinion.”